Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 25 full-time employees. The company went IPO on 2004-07-27. The firm is focused on developing therapies across a range of cancers with unmet medical needs. The firm is focused on tumor vulnerabilities with treatment combinations of onvansertib, its selective PLK1 inhibitor, and standard of care (SoC) therapeutics. The firm has five ongoing clinical trials of onvansertib, including two trials (TROV-054 and ONSEMBLE) in second-line treatment in patients with KRAS-mutated Metastatic Colorectal Cancer (mCRC), one trial in second-line treatment in patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), and two investigator-initiated trials in patients with unresectable locally advanced or metastatic Triple Negative Breast Cancer (TNBC) and relapsed Small Cell Lung Cancer (SCLC). The firm has third-party manufacturers and distributors to supply and distribute onvansertib used in its clinical studies and nonclinical development programs.